| Primary |
| Atrial Fibrillation |
20.0% |
| Product Used For Unknown Indication |
13.1% |
| Thrombosis Prophylaxis |
11.2% |
| Cerebrovascular Accident Prophylaxis |
8.3% |
| Acute Coronary Syndrome |
8.1% |
| Ill-defined Disorder |
7.9% |
| Prophylaxis |
3.7% |
| Drug Use For Unknown Indication |
3.5% |
| Hypertension |
3.3% |
| Pulmonary Embolism |
3.3% |
| Knee Arthroplasty |
2.8% |
| Pain |
2.7% |
| Deep Vein Thrombosis |
2.6% |
| Hip Arthroplasty |
2.2% |
| Analgesic Therapy |
1.4% |
| Anticoagulant Therapy |
1.4% |
| Coronary Artery Disease |
1.3% |
| Blood Pressure Abnormal |
1.1% |
| Cardiac Failure |
1.1% |
| Dermatitis |
1.1% |
|
| Pulmonary Embolism |
17.2% |
| Deep Vein Thrombosis |
8.9% |
| Gastrointestinal Haemorrhage |
8.3% |
| Subdural Haematoma |
6.3% |
| Haemoglobin Decreased |
5.7% |
| Haemorrhage |
4.7% |
| Melaena |
4.7% |
| Cerebrovascular Accident |
4.2% |
| Post Procedural Haemorrhage |
4.2% |
| Thrombosis |
4.2% |
| International Normalised Ratio Increased |
3.6% |
| Post Procedural Haematoma |
3.6% |
| Rectal Haemorrhage |
3.6% |
| Haematuria |
3.1% |
| Lower Gastrointestinal Haemorrhage |
3.1% |
| Renal Impairment |
3.1% |
| Vascular Pseudoaneurysm |
3.1% |
| Vomiting |
3.1% |
| Haematochezia |
2.6% |
| Renal Failure Acute |
2.6% |
|
| Secondary |
| Acute Coronary Syndrome |
14.1% |
| Product Used For Unknown Indication |
12.1% |
| Thrombosis Prophylaxis |
9.8% |
| Dermatitis |
9.0% |
| Cerebrovascular Accident Prophylaxis |
8.5% |
| Atrial Fibrillation |
8.4% |
| Pulmonary Embolism |
4.7% |
| Hypertension |
4.6% |
| Prophylaxis |
4.0% |
| Drug Use For Unknown Indication |
3.7% |
| Ill-defined Disorder |
3.2% |
| Urinary Tract Infection |
2.9% |
| Cardiac Failure |
2.7% |
| Pain |
2.7% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Prophylaxis Urinary Tract Infection |
1.8% |
| Depression |
1.7% |
| Knee Arthroplasty |
1.7% |
| Tuberculosis |
1.5% |
| Hip Arthroplasty |
1.1% |
|
| Hepatic Enzyme Increased |
10.7% |
| Pyrexia |
10.7% |
| Pulmonary Embolism |
7.1% |
| Deep Vein Thrombosis |
5.1% |
| Jaundice Cholestatic |
5.1% |
| Subdural Haematoma |
5.1% |
| Alanine Aminotransferase Increased |
4.6% |
| Mental Status Changes |
4.6% |
| Oesophagitis Haemorrhagic |
4.6% |
| Post Procedural Haemorrhage |
4.6% |
| Aortic Dissection |
4.1% |
| Cardiac Failure Congestive |
4.1% |
| Congestive Cardiomyopathy |
4.1% |
| Peritoneal Haemorrhage |
4.1% |
| Vascular Pseudoaneurysm |
4.1% |
| Haemoglobin Decreased |
3.6% |
| International Normalised Ratio Increased |
3.6% |
| Post Procedural Haematoma |
3.6% |
| Renal Impairment |
3.6% |
| Wound Secretion |
3.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.2% |
| Prophylaxis |
7.5% |
| Hypertension |
6.3% |
| B-cell Lymphoma |
5.9% |
| Atrial Fibrillation |
5.5% |
| Diabetes Mellitus |
5.1% |
| Rheumatoid Arthritis |
5.1% |
| Pain |
3.4% |
| Plasma Cell Myeloma |
2.0% |
| Drug Use For Unknown Indication |
1.8% |
| Hypercholesterolaemia |
1.8% |
| Adverse Event |
1.4% |
| Embolism |
1.4% |
| Hyperlipidaemia |
1.4% |
| Adenocarcinoma Of Colon |
1.2% |
| Arthropathy |
1.2% |
| Colorectal Cancer Metastatic |
1.2% |
| Osteoporosis |
1.2% |
| Polymyalgia Rheumatica |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
|
| Pneumonia |
8.5% |
| Troponin T Increased |
8.5% |
| Faeces Discoloured |
6.8% |
| Pulmonary Embolism |
6.8% |
| Thrombocytopenia |
6.8% |
| Tonsillar Ulcer |
6.8% |
| Wound Infection Staphylococcal |
6.8% |
| Atrial Fibrillation |
5.1% |
| Overdose |
5.1% |
| Renal Failure Acute |
5.1% |
| Drug Ineffective |
3.4% |
| Dyspnoea |
3.4% |
| Fear |
3.4% |
| Liver Disorder |
3.4% |
| Pneumonitis |
3.4% |
| Rhabdomyolysis |
3.4% |
| Staphylococcal Sepsis |
3.4% |
| Urticaria |
3.4% |
| Vomiting |
3.4% |
| Weight Decreased |
3.4% |
|
| Interacting |
| Acute Coronary Syndrome |
37.4% |
| Product Used For Unknown Indication |
15.1% |
| Atrial Fibrillation |
8.3% |
| Ill-defined Disorder |
5.5% |
| Cerebrovascular Accident Prophylaxis |
4.9% |
| Drug Use For Unknown Indication |
4.4% |
| Thrombosis Prophylaxis |
3.6% |
| Cardiovascular Disorder |
2.9% |
| Diuretic Therapy |
2.3% |
| Blood Cholesterol Increased |
2.1% |
| Blood Pressure High |
2.1% |
| Anticoagulant Therapy |
1.8% |
| Hypertension |
1.8% |
| Cardiac Disorder |
1.3% |
| Postoperative Analgesia |
1.3% |
| Analgesic Therapy |
1.0% |
| Blood Pressure Abnormal |
1.0% |
| Cancer |
1.0% |
| Cardiovascular Event Prophylaxis |
1.0% |
| Diabetes Mellitus |
1.0% |
|
| Upper Gastrointestinal Haemorrhage |
10.1% |
| Drug Interaction |
8.9% |
| Vascular Pseudoaneurysm |
8.9% |
| Post Procedural Haemorrhage |
7.6% |
| Angina Unstable |
6.3% |
| Haemoglobin Decreased |
6.3% |
| Haemorrhage |
6.3% |
| Sudden Death |
6.3% |
| Anaemia |
5.1% |
| Gastrointestinal Haemorrhage |
5.1% |
| Haemoptysis |
3.8% |
| Haemorrhage Intracranial |
3.8% |
| Intestinal Obstruction |
3.8% |
| Epistaxis |
2.5% |
| Haematuria |
2.5% |
| Laboratory Test Abnormal |
2.5% |
| Microcytic Anaemia |
2.5% |
| Pharyngeal Haemorrhage |
2.5% |
| Post Procedural Haematoma |
2.5% |
| Rectal Haemorrhage |
2.5% |
|
